{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T07:40:39Z","timestamp":1768981239701,"version":"3.49.0"},"update-to":[{"DOI":"10.1002\/14651858.cd010625","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2015,9,23]],"date-time":"2015-09-23T00:00:00Z","timestamp":1442966400000}}],"reference-count":95,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010625.pub2","type":"journal-article","created":{"date-parts":[[2015,9,23]],"date-time":"2015-09-23T20:00:03Z","timestamp":1443038403000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Clozapine for psychotic disorders in adults with intellectual disabilities"],"prefix":"10.1002","volume":"2015","author":[{"given":"Muhammad","family":"Ayub","sequence":"first","affiliation":[{"name":"Queen's University; Department of Psychiatry; 191 Portsmouth Avenue Kingston ON Canada K7M 8A6"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid","family":"Saeed","sequence":"additional","affiliation":[{"name":"Queen's University; Department of Psychiatry; 191 Portsmouth Avenue Kingston ON Canada K7M 8A6"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tariq A","family":"Munshi","sequence":"additional","affiliation":[{"name":"Kingston General Hospital; Department of Psychiatry; Frontenac Clinical Services 385 Princess Street Kingston UK ON K7L 1B9"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farooq","family":"Naeem","sequence":"additional","affiliation":[{"name":"Queen's University; Department of Psychiatry; 191 Portsmouth Avenue Kingston ON Canada K7M 8A6"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,9,23]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD010625.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"75-84","DOI":"10.1016\/S0891-4222(99)00031-1","article-title":"Side effect profiles of atypical antipsychotics, typical antipsychotics, or no psychotropic medications in persons with mental retardation","volume":"21","author":"Advokat","year":"2000","journal-title":"Research in Developmental Disabilities"},{"issue":"Pt 3","key":"10.1002\/14651858.CD010625.pub2-BIB0002|cit2","first-page":"203","article-title":"A critical appraisal of recent drug research in mental retardation: the Coldwater studies","volume":"30","author":"Aman","year":"1986","journal-title":"Journal of Mental Deficiency Research"},{"issue":"5","key":"10.1002\/14651858.CD010625.pub2-BIB0003|cit3","first-page":"500","article-title":"Psychotropic drugs in group homes: prevalence and relation to demographic\/psychiatric variables","volume":"99","author":"Aman","year":"1995","journal-title":"American Journal of Mental Retardation"},{"issue":"4","key":"10.1002\/14651858.CD010625.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"253-63","DOI":"10.1002\/(SICI)1098-2779(1999)5:4<253::AID-MRDD2>3.0.CO;2-R","article-title":"Atypical antipsychotics in persons with developmental disabilities","volume":"5","author":"Aman","year":"1999","journal-title":"Mental Retardation and Developmental Disabilities Research Reviews"},{"issue":"1","key":"10.1002\/14651858.CD010625.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1017\/S1092852900020034","article-title":"Treatment-refractory schizoaffective disorder in a patient with dyke-davidoff-masson syndrome","volume":"14","author":"Amann","year":"2009","journal-title":"CNS Spectrums"},{"issue":"1","key":"10.1002\/14651858.CD010625.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4088\/JCP.v61n0106","article-title":"Clozapine treatment in a population of adults with mental retardation","volume":"61","author":"Antonacci","year":"2000","journal-title":"Journal of Clinical Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD010625.pub2-BIB0007|cit7","first-page":"618","article-title":"Psychotropic medication of mentally retarded residents in community long-term care facilities","volume":"93","author":"Buck","year":"1989","journal-title":"American Journal on Mental Retardation"},{"issue":"1","key":"10.1002\/14651858.CD010625.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"93-5","DOI":"10.1176\/jnp.10.1.93","article-title":"Use of clozapine in 10 mentally retarded adults","volume":"10","author":"Buzan","year":"1998","journal-title":"Journal of Neuropsychiatry and Clinical Neurosciences"},{"issue":"10","key":"10.1002\/14651858.CD010625.pub2-BIB0009|cit9","first-page":"440","article-title":"The use of clozapine in a mentally retarded and aggressive population","volume":"55","author":"Cohen","year":"1994","journal-title":"Journal of Clinical Psychiatry"},{"issue":"97","key":"10.1002\/14651858.CD010625.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1179\/096979503799104101","article-title":"Audit on high dose antipsychotic medication in three tertiary services for people with learning disability","volume":"49","author":"Dalvi","year":"2003","journal-title":"British Journal of Developmental Disabilities"},{"issue":"7","key":"10.1002\/14651858.CD010625.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"659-67","DOI":"10.1111\/j.1365-2788.2010.01275.x","article-title":"Use of antipsychotic drugs in individuals with intellectual disability (ID) in the Netherlands: prevalence and reasons for prescription","volume":"54","author":"Kuijper","year":"2010","journal-title":"Journal of Intellectual Disability Research"},{"issue":"104","key":"10.1002\/14651858.CD010625.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1179\/096979507799103513","article-title":"Audit on the use of antipsychotic medication in a community sample of people with learning disability","volume":"53","author":"Dhumad","year":"2007","journal-title":"British Journal of Developmental Disabilities"},{"issue":"8","key":"10.1002\/14651858.CD010625.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1177\/070674370104600807","article-title":"Atypical antipsychotics use in treating adolescents and young adults with developmental disabilities","volume":"46","author":"Friedlander","year":"2001","journal-title":"Canadian Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD010625.pub2-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1192\/bjp.bp.110.085670","article-title":"Safety of antipsychotics in people with intellectual disability","volume":"199","author":"Frighi","year":"2011","journal-title":"British Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD010625.pub2-BIB0015|cit15","first-page":"5","article-title":"Low-dose antipsychotics generally safe in patients with intellectual disability, but caution still advised","volume":"23","author":"Frighi","year":"2012","journal-title":"Brown University Psychopharmacology Update"},{"issue":"Pt 7","key":"10.1002\/14651858.CD010625.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1365-2788.2005.00708.x","article-title":"Clozapine treatment of psychosis associated with velo-cardio-facial syndrome: benefits and risks","volume":"49","author":"Gladston","year":"2005","journal-title":"Journal of Intellectual Disability Research"},{"issue":"4","key":"10.1002\/14651858.CD010625.pub2-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1108\/20441281211236661","article-title":"Antipsychotic prescribing in people with intellectual disabilities: a clinical audit","volume":"6","author":"Griffiths","year":"2012","journal-title":"Advances in Mental Health and Intellectual Disabilities"},{"issue":"1","key":"10.1002\/14651858.CD010625.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1023\/A:1005626100084","article-title":"Brief report: effects of clozapine on self-injurious behavior of two risperidone nonresponders with mental retardation","volume":"31","author":"Hammock","year":"2001","journal-title":"Journal of Autism and Developmental Disorders"},{"issue":"1","key":"10.1002\/14651858.CD010625.pub2-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"32-3","DOI":"10.1017\/S0790966700005024","article-title":"The use of clozapine in an individual with moderate intellectual disability, aggressive behaviour and resistant psychosis","volume":"16","author":"Kamal","year":"1999","journal-title":"Irish Journal of Psychological Medicine"},{"issue":"2","key":"10.1002\/14651858.CD010625.pub2-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"73-89","DOI":"10.1002\/hup.748","article-title":"Reviewing the use of antipsychotic drugs in people with intellectual disability","volume":"21","author":"Malfa","year":"2006","journal-title":"Human Psychopharmacology: Clinical and Experimental"},{"issue":"5","key":"10.1002\/14651858.CD010625.pub2-BIB0021|cit21","first-page":"323","article-title":"Clozapine in three individuals with mild mental retardation and treatment-refractory psychiatric disorders","volume":"32","author":"Pary","year":"1994","journal-title":"Mental Retardation"},{"issue":"Pt 1","key":"10.1002\/14651858.CD010625.pub2-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/j.1365-2788.2006.00865.x","article-title":"Prevention of clozapine-induced granulocytopenia\/agranulocytosis with granulocyte-colony stimulating factor (G-CSF) in an intellectually disabled patient with schizophrenia","volume":"51","author":"Rajagopal","year":"2007","journal-title":"Journal of Intellectual Disability Research"},{"issue":"2","key":"10.1002\/14651858.CD010625.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/136515002753724144","article-title":"Safety and efficacy of long-term low-dose clozapine aftercare treatment in a patient with learning difficulties who suffered from neuroleptic malignant syndrome","volume":"6","author":"Reznik","year":"2002","journal-title":"International Journal of Psychiatry in Clinical Practice"},{"issue":"1","key":"10.1002\/14651858.CD010625.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0010-440X(94)90166-X","article-title":"The use of clozapine in borderline-intellectual-functioning and mentally retarded schizophrenic patients","volume":"35","author":"Sajatovic","year":"1994","journal-title":"Comprehensive Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD010625.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2190\/4EC8-H122-HJAL-YDLV","article-title":"Clozapine therapy in patients with neuroleptic illness","volume":"25","author":"Sajatovic","year":"1995","journal-title":"International Journal of Psychiatry in Medicine"},{"issue":"2","key":"10.1002\/14651858.CD010625.pub2-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"120-9","DOI":"10.1002\/mrdd.1410010208","article-title":"Clinical trials of D1 and D2 dopamine modulating drugs and self-injury in mental retardation and developmental disability","volume":"1","author":"Schroeder","year":"1995","journal-title":"Mental Retardation and Developmental Disabilities Research Reviews"},{"issue":"6","key":"10.1002\/14651858.CD010625.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"344-52","DOI":"10.1080\/714044396","article-title":"Nothing new under the sun: clozapine rechallenge following a life-threatening medical event in a patient with psychiatric illness and developmental disability","volume":"11","author":"Shedlack","year":"2003","journal-title":"Harvard Review of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD010625.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"52","DOI":"10.4088\/JCP.v66n0108","article-title":"Assessing the utility of atypical antipsychotic medication in adults with mild mental retardation and comorbid psychiatric disorders","volume":"66","author":"Shedlack","year":"2005","journal-title":"Journal of Clinical Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD010625.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1135-41","DOI":"10.1016\/j.ridd.2010.07.003","article-title":"The use of clozapine among individuals with intellectual disability: a review","volume":"31","author":"Singh","year":"2010","journal-title":"Research in Developmental Disabilities"},{"issue":"Pt 6","key":"10.1002\/14651858.CD010625.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/j.1365-2788.2004.00626.x","article-title":"The use of clozapine in adults with intellectual disability","volume":"48","author":"Thalayasingam","year":"2004","journal-title":"Journal of Intellectual Disability Research"},{"issue":"107","key":"10.1002\/14651858.CD010625.pub2-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1179\/096979508799103288","article-title":"Use of atypical antipsychotics in people with intellectual disability - is a atypical?","volume":"54","author":"Tin","year":"2008","journal-title":"British Journal of Developmental Disabilities"},{"issue":"5","key":"10.1002\/14651858.CD010625.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1097\/00004583-199406000-00005","article-title":"Clozapine for early developmental delays with childhood-onset schizophrenia: protocol and 15-month outcome","volume":"33","author":"Towbin","year":"1994","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD010625.pub2-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"183","DOI":"10.4274\/npa.y6378","article-title":"Tardive dyskinesia due to olanzapine in an adolescent with psychosis and its treatment with clozapine","volume":"50","author":"Tufan","year":"2013","journal-title":"Archives of Neuropsychiatry"},{"issue":"6","key":"10.1002\/14651858.CD010625.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"2121-33","DOI":"10.1016\/j.ridd.2011.07.031","article-title":"Efficacy of atypical antipsychotic medication in the management of behaviour problems in children with intellectual disabilities and borderline intelligence: a systematic review","volume":"32","author":"Unwin","year":"2011","journal-title":"Research in Developmental Disabilities"},{"issue":"5","key":"10.1002\/14651858.CD010625.pub2-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1055\/s-0028-1094426","article-title":"The treatment of behavior disorders in idiocy and imbecility with clozapine","volume":"7","author":"Vvncke","year":"1974","journal-title":"Pharmakopsychiatrie\/Neuro-Psychopharmakologie"},{"issue":"2-3","key":"10.1002\/14651858.CD010625.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"273-6","DOI":"10.1016\/j.psychres.2004.02.018","article-title":"Clozapine: weight gain in a pair of monozygotic twins concordant for schizophrenia and mild mental retardation","volume":"133","author":"Wehmeier","year":"2005","journal-title":"Psychiatry Research"},{"key":"10.1002\/14651858.CD010625.pub2-BIB0037|cit37","unstructured":"White T Pigue T Burton E A case study: the comparative effects of clozapine, olanzapine, valproic acid, and lithium on the WBC and ANC in an intellectually disabled individual. Poster submissions of the College of Psychiatric and Neurologic Pharmacists 2010 Annual Meeting Journal of Pharmacy Practice 2010 182 10.1177\/0897190010365987"},{"issue":"8","key":"10.1002\/14651858.CD010625.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"600-20","DOI":"10.1016\/j.euroneuro.2011.04.001","article-title":"Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies","volume":"21","author":"Zuddas","year":"2011","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD010625.pub2-BIB0039|cit39","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"issue":"2","key":"10.1002\/14651858.CD010625.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2165\/00019053-200826020-00005","article-title":"The burden of schizophrenia on caregivers: a review","volume":"26","author":"Awad","year":"2008","journal-title":"Pharmacoeconomics"},{"issue":"13","key":"10.1002\/14651858.CD010625.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta7130","article-title":"A systematic review of atypical antipsychotic drugs in schizophrenia","volume":"7","author":"Bagnall","year":"2003","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD010625.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"British Journal of Psychiatry"},{"issue":"7108","key":"10.1002\/14651858.CD010625.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD010625.pub2-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1017\/S0790966700002846","article-title":"Use of clozapine in a mental handicap hospital - report on the first 17 patients","volume":"14","author":"Boachie","year":"1997","journal-title":"Irish Journal of Psychological Medicine"},{"issue":"Pt 6","key":"10.1002\/14651858.CD010625.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1365-2788.2004.00623.x","article-title":"Schizophrenia-spectrum psychoses in people with and without intellectual disability","volume":"48","author":"Bouras","year":"2004","journal-title":"Journal of Intellectual Disability Research"},{"issue":"6","key":"10.1002\/14651858.CD010625.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1192\/bjp.bp.114.151837","article-title":"Response to clozapine in a clinically identifiable subtype of schizophrenia","volume":"206","author":"Butcher","year":"2015","journal-title":"British Journal of Psychiatry"},{"issue":"10","key":"10.1002\/14651858.CD010625.pub2-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1056\/NEJM199403103301006","article-title":"Schizophrenia","volume":"330","author":"Carpenter","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD010625.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1176\/appi.ajp.158.4.518","article-title":"Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials","volume":"158","author":"Chakos","year":"2001","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD010625.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1365-2788.47.s1.2.x","article-title":"Psychiatric diagnosis, intellectual disabilities and Diagnostic Criteria for Psychiatric Disorders for Use with Adults with Learning Disabilities\/Mental Retardation (DC-LD)","volume":"47 Suppl 1","author":"Cooper","year":"2003","journal-title":"Journal of Intellectual Disability Research"},{"key":"10.1002\/14651858.CD010625.pub2-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1192\/bjp.bp.106.022483","article-title":"Mental ill-health in adults with intellectual disabilities: prevalence and associated factors","volume":"190","author":"Cooper","year":"2007","journal-title":"British Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD010625.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/0957154X07070335","article-title":"The history of clozapine and its emergence in the US market: a review and analysis","volume":"18","author":"Crilly","year":"2007","journal-title":"History of Psychiatry"},{"issue":"Pt 6","key":"10.1002\/14651858.CD010625.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1046\/j.1365-2788.2001.00374.x","article-title":"Mental disorder in adults with intellectual disability. 1: Prevalence of functional psychiatric illness among a community-based population aged between 16 and 64 years","volume":"45","author":"Deb","year":"2001","journal-title":"Journal of Intellectual Disability Research"},{"issue":"6","key":"10.1002\/14651858.CD010625.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians\u2019 patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD010625.pub2-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1192\/bjp.bp.110.088690","article-title":"Clozapine: dangerous orphan or neglected friend?","volume":"198","author":"Farooq","year":"2011","journal-title":"British Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD010625.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD010625.pub2-BIB0056|cit56","unstructured":"Glover G Ayub M Improving Health and Lives: Learning Disabilities Observatory. How people with learning disabilities die (accessed 20 February 2015)"},{"issue":"9","key":"10.1002\/14651858.CD010625.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intra-class correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD010625.pub2-BIB0058|cit58","volume-title":"Abnormal Involuntary Movements, in ECDEU Assessment Manual for Psychopharmacology US Department of Health, Education, and Welfare","author":"Guy","year":"1976"},{"issue":"11","key":"10.1002\/14651858.CD010625.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD010625.pub2-BIB0060|cit60","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD010625.pub2-BIB0061|cit61","first-page":"22","article-title":"A historical perspective of clozapine","volume":"60 Suppl 12","author":"Hippius","year":"1999","journal-title":"Journal of Clinical Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD010625.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1192\/bjp.166.5.654","article-title":"A brief mental health outcome scale: reliability and validity of the Global Assessment of Functioning (GAF)","volume":"166","author":"Jones","year":"1995","journal-title":"British Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD010625.pub2-BIB0063|cit63","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophrenia Bulletin"},{"issue":"7","key":"10.1002\/14651858.CD010625.pub2-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"e69930","DOI":"10.1371\/journal.pone.0069930","article-title":"A re-analysis of the Cochrane library data: the dangers of unobserved heterogeneity in meta-analyses","volume":"8","author":"Kontopantelis","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1002\/14651858.CD010625.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/bmb\/ldv017","article-title":"Antipsychotic medication in schizophrenia: a review","volume":"114","author":"Lally","year":"2015","journal-title":"British Medical Bulletin"},{"issue":"3","key":"10.1002\/14651858.CD010625.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1600-0447.2008.01213.x","article-title":"Rates and predictors of remission and recovery during 3\u00a0years in 392 never-treated patients with schizophrenia","volume":"118","author":"Lambert","year":"2008","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"9657","key":"10.1002\/14651858.CD010625.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD010625.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/schbul\/sbl025","article-title":"Is the superior efficacy of new generation antipsychotics an artefact of LOCF?","volume":"33","author":"Leucht","year":"2007","journal-title":"Schizophrenia Bulletin"},{"issue":"1","key":"10.1002\/14651858.CD010625.pub2-BIB0069|cit69","first-page":"23","article-title":"Cost of schizophrenia in England","volume":"10","author":"Mangalore","year":"2007","journal-title":"Journal of Mental Health Policy and Economics"},{"issue":"2","key":"10.1002\/14651858.CD010625.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ridd.2010.12.018","article-title":"Prevalence of intellectual disability: a meta-analysis of population-based studies","volume":"32","author":"Maulik","year":"2011","journal-title":"Research in Developmental Disabilities"},{"issue":"4","key":"10.1002\/14651858.CD010625.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/schbul\/14.4.515","article-title":"A selective review of recent North American long-term follow up studies of schizophrenia","volume":"14","author":"McGlashan","year":"1988","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD010625.pub2-BIB0072|cit72","volume-title":"The Prevalence of Psychiatric Morbidity Among Adults Living in Private Households: OPCS Survey of Psychiatric Morbidity in Great Britain, Report 1","author":"Meltzer","year":"1995"},{"key":"10.1002\/14651858.CD010625.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0079-6123(08)00909-6","article-title":"In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems","volume":"172","author":"Meltzer","year":"2008","journal-title":"Progress in Brain Research"},{"issue":"10","key":"10.1002\/14651858.CD010625.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1017\/S0033291706007951","article-title":"A systematic review of longitudinal outcome studies of first-episode psychosis","volume":"36","author":"Menezes","year":"2006","journal-title":"Psychological Medicine"},{"issue":"3","key":"10.1002\/14651858.CD010625.pub2-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.psc.2007.04.007","article-title":"Epidemiology of schizophrenia: review of findings and myths","volume":"30","author":"Messias","year":"2007","journal-title":"Psychiatric Clinics of North America"},{"key":"10.1002\/14651858.CD010625.pub2-BIB0076|cit76","first-page":"14","article-title":"Review and management of clozapine side effects","volume":"61 Suppl 8","author":"Millar","year":"2000","journal-title":"Journal of Clinical Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD010625.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1352\/0895-8017(2003)108<293:POEAAH>2.0.CO;2","article-title":"Prevalence of epilepsy and associated health service utilization and mortality among patients with intellectual disability","volume":"108","author":"Morgan","year":"2003","journal-title":"American Journal on Mental Retardation"},{"issue":"3","key":"10.1002\/14651858.CD010625.pub2-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1192\/bjp.168.3.359","article-title":"Validity of the schizophrenia diagnosis of the psychiatric assessment schedule for adults with developmental disability (PAS-ADD)","volume":"168","author":"Moss","year":"1996","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD010625.pub2-BIB0079|cit79","unstructured":"Novartis Pharmacetical Corporation Highlights of prescribing information http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/Clozaril.pdf"},{"issue":"25","key":"10.1002\/14651858.CD010625.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"1907-9","DOI":"10.1056\/NEJM200006223422511","article-title":"Randomized trials of observational tribulations","volume":"342","author":"Pocock","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD010625.pub2-BIB0081|cit81","first-page":"219","article-title":"The effects of clozapine on severely aggressive psychiatric inpatients in a state hospital","volume":"54","author":"Ratey","year":"1993","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD010625.pub2-BIB0082|cit82","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"5","key":"10.1002\/14651858.CD010625.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3109\/10673229509017150","article-title":"Clozapine, mental retardation and severe psychiatric illness: clinical response in the first year","volume":"2","author":"Rubin","year":"1995","journal-title":"Harvard Review of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD010625.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/schbul\/17.2.247","article-title":"Update on the clinical efficacy and side effects of clozapine","volume":"17","author":"Safferman","year":"1991","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD010625.pub2-BIB0085|cit85","volume-title":"Intellectual Disability: Definition, Classification, and Systems of Supports","author":"Schalock","year":"2010"},{"key":"10.1002\/14651858.CD010625.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"8","key":"10.1002\/14651858.CD010625.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.neubiorev.2010.01.016","article-title":"Neuroimaging predictors of transition to psychosis - a systematic review and meta-analysis","volume":"34","author":"Smieskova","year":"2010","journal-title":"Neuroscience and Biobehavioral Reviews"},{"issue":"1","key":"10.1002\/14651858.CD010625.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-2007-993224","article-title":"Clozapine in China","volume":"41","author":"Tang","year":"2008","journal-title":"Pharmacopsychiatry"},{"issue":"2","key":"10.1002\/14651858.CD010625.pub2-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3969\/j.issn.1002-0829.2012.02.006","article-title":"Proper use of clozapine: experiences in China","volume":"24","author":"Wang","year":"2012","journal-title":"Shanghai Archives of Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD010625.pub2-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1177\/0269881108093588","article-title":"Outcomes for schizophrenia patients with clozapine treatment: how good does it get?","volume":"23","author":"Wheeler","year":"2009","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD010625.pub2-BIB0091|cit91","volume-title":"International Classification of Diseases (ICD-9)","author":"World Health Organization","year":"1979"},{"key":"10.1002\/14651858.CD010625.pub2-BIB0092|cit92","volume-title":"The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines","author":"World Health Organization","year":"1992"},{"key":"10.1002\/14651858.CD010625.pub2-BIB0093|cit93","volume-title":"Schizophrenia and Public Health","author":"Barbato","year":"1997"},{"issue":"6","key":"10.1002\/14651858.CD010625.pub2-BIB0094|cit94","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1093\/schbul\/sbs135","article-title":"The myth of schizophrenia as a progressive brain disease","volume":"39","author":"Zipursky","year":"2013","journal-title":"Schizophrenia Bulletin"},{"issue":"6","key":"10.1002\/14651858.CD010625.pub2-BIB0095|cit95","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010625","article-title":"Clozapine for psychotic disorders in adults with intellectual disabilities","author":"Paul","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD010625.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T12:33:51Z","timestamp":1656333231000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD010625.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Developmental, Psychosocial and Learning Problems Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,9,23]]},"references-count":95,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2015,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010625.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,23]]}}}